Invasive Testing, Noninvasive Testing, and Rising Maternal Screening Methods for Preeclampsia and Preterm Labor
NEEDHAM, MA--(Marketwired - June 06, 2016) - Insight Pharma Reports, a division of Healthtech Publishing, provides the life science sciences community the report entitled: Prenatal Diagnostics: Invasive Testing, Noninvasive Testing, and Rising Maternal Screening Methods for Preeclampsia and Preterm Labor. This report discusses improvements in invasive procedures (karyotyping vs. cytogenetics), and the rise of noninvasive screening methods and their impact on prenatal healthcare.
Insight Pharma Report's Prenatal Diagnostics report covers:
For more information on these reports visit: InsightPharmaReports.com/Prenatal-Diagnostic-Testing
About Insight Pharma Reports (www.insightpharmareports.com)
Insight Pharma Reports, a division of Healthtech Publishing, is the premier life sciences information provider offering unparalleled coverage of key issues in drug discovery and development. The reports are used by leading pharmaceutical, biotech, diagnostic, and other life science companies to keep abreast of the latest developments in pharmaceutical R&D and their potential applications and business impacts. The reports are written by experts in consulting and industry, and are supported by hundreds of hours of primary and secondary research. Insight Pharma Reports provide comprehensive coverage of salient issues in a concise, well-organized format.
About Healthtech Publishing
(www.healthtechpublishing.com)
Healthtech Publishing, a division of Cambridge Healthtech Institute, provides the life science communities with business critical intelligence through research reports and digital news, helping decision makers to gain competitive advantage and make strategic decisions. Our portfolio consists of Insight Pharma Reports' vast research reports collection and three niche digital subscription products: Bio-IT World, Clinical Informatics News and Diagnostics World.
Contact Information:
For more information:
Daniel Miller
Insight Pharma Reports
dmiller@insightpharmareports.com